Agios Pharmaceuticals logo
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
June 21, 2021 07:00 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for...
Agios Pharmaceuticals logo
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
June 11, 2021 03:00 ET | Agios Pharmaceuticals, Inc.
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast...
Agios Pharmaceuticals logo
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
June 11, 2021 03:00 ET | Agios Pharmaceuticals, Inc.
– Study Met Primary Endpoint; Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 16 of 20 (80%) Patients During Weeks 4-12 – – Mitapivat Safety Profile Consistent with Previously...
Agios Pharmaceuticals logo
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress
May 12, 2021 10:00 ET | Agios Pharmaceuticals, Inc.
– Agios to Host Investor Webcast on June 11 at 7:30 a.m. ET – CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular...
Agios Pharmaceuticals logo
Agios Reports Business Highlights and First Quarter 2021 Financial Results
April 29, 2021 07:00 ET | Agios Pharmaceuticals, Inc.
– Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency and Phase 2 Study of Mitapivat in Thalassemia Accepted for Presentation at EHA 2021 Virtual Congress...
Agios Pharmaceuticals logo
Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
April 15, 2021 07:00 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
Agios Pharmaceuticals logo
Agios Announces Closing of Oncology Business Sale to Servier
April 01, 2021 07:00 ET | Agios Pharmaceuticals, Inc.
Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio Agios Enters Into Agreement to Repurchase Approximately 10% of Its...
Agios Pharmaceuticals logo
Agios Shareholders Approve Sale of Oncology Business to Servier
March 25, 2021 16:01 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced...
Agios Pharmaceuticals logo
Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
March 18, 2021 07:00 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today...
Agios Pharmaceuticals logo
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
March 01, 2021 07:00 ET | Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today...